You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 268 Development of FT825/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
268 Development of FT825/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hosking M, Shirinbak S, Omilusik K, et al
268 Development of FT825/ONO-8250: an off-the-shelf CAR-T cell with preferential HER2 targeting and engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0268